PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD
Status:
Completed
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
This is a phase 3 double-blind randomized study to study the efficacy and safety of
intravenous ATB200 Co-administered with oral AT2221 in adult subjects with Late Onset Pompe
Disease compared with Alglucosidase Alfa/placebo.